Financial news, mergers and acquisitions, partnerships, and alliances.
Last month, the company announced two transactions that it said would enable it to regain compliance with the Nasdaq's listing requirement.
Onkos Molecular Diagnostics is looking for a US partner to commercialize its 11 miRNA-based mir-THYpe test, which it believes offers advantages over tests on the market.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment.